The Geisinger Health System, an integrated health services organization serving more than 2.6 million residents of 42 counties in central and northeastern Pennsylvania, has purchased Mazor Robotics Ltd’ surgical guidance system for spine procedures. Mazor’s technology is the only robotic system specifically for spine surgery currently available in the marketplace.
Geisinger Acquires a Mazor Robotics Surgical System
1 min read Premium comments
Secondary
“The Renaissance system has proven to provide patients with scoliosis significantly better outcomes from procedures that result in shorter hospital stays, quicker recoveries and reduces intraoperative radiation exposure, ” said Michael Suk, M.D., chairman, department of orthopedic surgery, Geisinger Health System, in a September 13 press release. “The exceptional precision and safety of the Renaissance system is a drastic improvement over freehand surgery and it will help patients feel even more confident in the high-quality care they receive at Geisinger, especially during complicated spine procedures.”
Meagan Fernandez, D.O., a fellowship-trained pediatric orthopedic surgeon at Geisinger, will perform pediatric spine surgeries with Renaissance. “Ultimately, our patients can rest assured knowing that they are receiving the absolute latest scoliosis treatment that is unavailable anywhere else in our region, ” said Fernandez. “The technology behind this system has been rigorously tested, and the results have been remarkable in terms of a patient’s recovery time and the eventual end result.”
Mazor Robotics is headquartered in Caesarea, Israel. Its robotics systems have been successfully used in the placement of over 20, 000 implants in the United States and Europe.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.